119 related articles for article (PubMed ID: 25461311)
1. Structural design and synthesis of arylalkynyl amide-type peroxisome proliferator-activated receptor γ (PPARγ)-selective antagonists based on the helix12-folding inhibition hypothesis.
Ohashi M; Gamo K; Tanaka Y; Waki M; Beniyama Y; Matsuno K; Wada J; Tenta M; Eguchi J; Makishima M; Matsuura N; Oyama T; Miyachi H
Eur J Med Chem; 2015 Jan; 90():53-67. PubMed ID: 25461311
[TBL] [Abstract][Full Text] [Related]
2. [Design and Synthesis of Peroxisome Proliferator-activated Receptor (PPAR) Gamma Antagonists Based on the Principle of Operation of Nuclear Receptor I].
Ohashi M; Miyachi H
Yakugaku Zasshi; 2017; 137(8):957-967. PubMed ID: 28768949
[TBL] [Abstract][Full Text] [Related]
3. Mode of peroxisome proliferator-activated receptor γ activation by luteolin.
Puhl AC; Bernardes A; Silveira RL; Yuan J; Campos JL; Saidemberg DM; Palma MS; Cvoro A; Ayers SD; Webb P; Reinach PS; Skaf MS; Polikarpov I
Mol Pharmacol; 2012 Jun; 81(6):788-99. PubMed ID: 22391103
[TBL] [Abstract][Full Text] [Related]
4. A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties.
Fujimura T; Kimura C; Oe T; Takata Y; Sakuma H; Aramori I; Mutoh S
J Pharmacol Exp Ther; 2006 Aug; 318(2):863-71. PubMed ID: 16682454
[TBL] [Abstract][Full Text] [Related]
5. Novel transcriptome profiling analyses demonstrate that selective peroxisome proliferator-activated receptor γ (PPARγ) modulators display attenuated and selective gene regulatory activity in comparison with PPARγ full agonists.
Tan Y; Muise ES; Dai H; Raubertas R; Wong KK; Thompson GM; Wood HB; Meinke PT; Lum PY; Thompson JR; Berger JP
Mol Pharmacol; 2012 Jul; 82(1):68-79. PubMed ID: 22496518
[TBL] [Abstract][Full Text] [Related]
6. The dipeptide H-Trp-Glu-OH shows highly antagonistic activity against PPARgamma: bioassay with molecular modeling simulation.
Ye F; Zhang ZS; Luo HB; Shen JH; Chen KX; Shen X; Jiang HL
Chembiochem; 2006 Jan; 7(1):74-82. PubMed ID: 16317783
[TBL] [Abstract][Full Text] [Related]
7. Arylalkynyl amide-type peroxisome proliferator-activated receptor γ (PPARγ)-selective antagonists covalently bind to the PPARγ ligand binding domain with a unique binding mode.
Yoshizawa M; Aoyama T; Itoh T; Miyachi H
Bioorg Med Chem Lett; 2022 May; 64():128676. PubMed ID: 35301139
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis.
Liu C; Feng T; Zhu N; Liu P; Han X; Chen M; Wang X; Li N; Li Y; Xu Y; Si S
Sci Rep; 2015 Apr; 5():9530. PubMed ID: 25827822
[TBL] [Abstract][Full Text] [Related]
9. JTP-426467 acts as a selective antagonist for peroxisome proliferator-activated receptor gamma in vitro and in vivo.
Nishiu J; Ito M; Ishida Y; Kakutani M; Shibata T; Matsushita M; Shindo M
Diabetes Obes Metab; 2006 Sep; 8(5):508-16. PubMed ID: 16918585
[TBL] [Abstract][Full Text] [Related]
10. Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo.
Nakano R; Kurosaki E; Yoshida S; Yokono M; Shimaya A; Maruyama T; Shibasaki M
Biochem Pharmacol; 2006 Jun; 72(1):42-52. PubMed ID: 16696951
[TBL] [Abstract][Full Text] [Related]
11. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
12. Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: drug-target interaction analyses.
Kakuta H; Kurosaki E; Niimi T; Gato K; Kawasaki Y; Suwa A; Honbou K; Yamaguchi T; Okumura H; Sanagi M; Tomura Y; Orita M; Yonemoto T; Masuzaki H
J Pharmacol Exp Ther; 2014 Apr; 349(1):10-20. PubMed ID: 24424487
[TBL] [Abstract][Full Text] [Related]
13. Luteolin inhibits adipogenic differentiation by regulating PPARgamma activation.
Park HS; Kim SH; Kim YS; Ryu SY; Hwang JT; Yang HJ; Kim GH; Kwon DY; Kim MS
Biofactors; 2009; 35(4):373-9. PubMed ID: 19353690
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships and key structural feature of pyridyloxybenzene-acylsulfonamides as new, potent, and selective peroxisome proliferator-activated receptor (PPAR) γ Agonists.
Rikimaru K; Wakabayashi T; Abe H; Tawaraishi T; Imoto H; Yonemori J; Hirose H; Murase K; Matsuo T; Matsumoto M; Nomura C; Tsuge H; Arimura N; Kawakami K; Sakamoto J; Funami M; Mol CD; Snell GP; Bragstad KA; Sang BC; Dougan DR; Tanaka T; Katayama N; Horiguchi Y; Momose Y
Bioorg Med Chem; 2012 May; 20(10):3332-58. PubMed ID: 22503460
[TBL] [Abstract][Full Text] [Related]
15. Hydrogen/deuterium-exchange (H/D-Ex) of PPARgamma LBD in the presence of various modulators.
Hamuro Y; Coales SJ; Morrow JA; Molnar KS; Tuske SJ; Southern MR; Griffin PR
Protein Sci; 2006 Aug; 15(8):1883-92. PubMed ID: 16823031
[TBL] [Abstract][Full Text] [Related]
16. Anti-adipogenic diarylheptanoids from Alnus hirsuta f. sibirica on 3T3-L1 cells.
Lee M; Song JY; Chin YW; Sung SH
Bioorg Med Chem Lett; 2013 Apr; 23(7):2069-73. PubMed ID: 23465614
[TBL] [Abstract][Full Text] [Related]
17. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
Díaz-Delfín J; Morales M; Caelles C
Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
[TBL] [Abstract][Full Text] [Related]
18. Cilostazol increases 3T3-L1 preadipocyte differentiation with improved glucose uptake associated with activation of peroxisome proliferator-activated receptor-gamma transcription.
Park SY; Lee JH; Kim KY; Kim EK; Yun SJ; Kim CD; Lee WS; Hong KW
Atherosclerosis; 2008 Dec; 201(2):258-65. PubMed ID: 18355828
[TBL] [Abstract][Full Text] [Related]
19. Artepillin C, as a PPARγ ligand, enhances adipocyte differentiation and glucose uptake in 3T3-L1 cells.
Choi SS; Cha BY; Iida K; Lee YS; Yonezawa T; Teruya T; Nagai K; Woo JT
Biochem Pharmacol; 2011 Apr; 81(7):925-33. PubMed ID: 21219874
[TBL] [Abstract][Full Text] [Related]
20. Selective effects of PPARgamma agonists and antagonists on human pre-adipocyte differentiation.
Leyvraz C; Suter M; Verdumo C; Calmes JM; Paroz A; Darimont C; Gaillard RC; Pralong FP; Giusti V
Diabetes Obes Metab; 2010 Mar; 12(3):195-203. PubMed ID: 19895635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
